Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

Por Khoury, H. Jean, Cortes, Jorge E., Kantarjian, Hagop M., Gambacorti-Passerini, Carlo, Baccarani, Michele, Kim, Dong-Wook, Zaritskey, Andrey, Countouriotis, Athena, Besson, Nadine, Leip, Eric, Kelly, Virginia, Brümmendorf, Tim H.
Publicado no Blood (2012)

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Por Kantarjian, Hagop M., Cortes, Jorge E., Kim, Dong-Wook, Khoury, H. Jean, Brümmendorf, Tim H., Porkka, Kimmo, Martinelli, Giovanni, Durrant, Simon, Leip, Eric, Kelly, Virginia, Turnbull, Kathleen, Besson, Nadine, Gambacorti-Passerini, Carlo
Publicado no Blood (2014)

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Por Cortes, Jorge E., Kantarjian, Hagop M., Brümmendorf, Tim H., Kim, Dong-Wook, Turkina, Anna G., Shen, Zhi-Xiang, Pasquini, Ricardo, Khoury, H. Jean, Arkin, Steven, Volkert, Angela, Besson, Nadine, Abbas, Richat, Wang, Junyuan, Leip, Eric, Gambacorti-Passerini, Carlo
Publicado no Blood (2011)

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

Por Gambacorti-Passerini, Carlo, Brümmendorf, Tim H, Kim, Dong-Wook, Turkina, Anna G, Masszi, Tamas, Assouline, Sarit, Durrant, Simon, Kantarjian, Hagop M, Khoury, H Jean, Zaritskey, Andrey, Shen, Zhi-Xiang, Jin, Jie, Vellenga, Edo, Pasquini, Ricardo, Mathews, Vikram, Cervantes, Francisco, Besson, Nadine, Turnbull, Kathleen, Leip, Eric, Kelly, Virginia, Cortes, Jorge E
Publicado em 2014